| Digg It |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Management > Malcolm Baldrige Values and Concepts Part 11 Systems Perspective |
|
Digg It - Malcolm Baldrige Values and Concepts Part 11 Systems Perspective
In this issue, I will share my experience acquired from the conglomerate and its operating companies. For the purpose of this article, I will articulate the Systems Perspective which is the last Values and Co According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product ncepts in Malcolm Baldrige Criteria. As before, I will use case studies to show how some of the companies implement them. To recap, below are the Eleven Core Values and Concepts of Baldrige Criteria: Visiona ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in ry Leadership | Customer-Driven Excellence | Organizational and Personal Learning | Valuing Employees and Partners | Agility | Focus on the Future | Managing for Innovation | Management by Fact | Public Responsibility an lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. d Citizenship | Focus on Results and Creating Value | Systems Perspective I will deal with the one of the Value in bold letters in this article as below: Articulated Systems Perspective The Baldrige Cri here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe teria provide a model which is a systems perspective for managing organization and its key business and operation processes to achieve performance excellence. The seven Baldrige Categories and its Values and concepts for d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro m the building blocks and the integrating mechanism for the system. However, successful management of overall performance requires organization specific synthesis, alignment, and integration. Synthesis means loo ucts have become life saving products for the pharmaceutical companies who doesnt have many innovative molecules in their product pipeline and have been inc king at your organization as a whole and builds upon key business requirements, strategic objectives and action plans. Alignment refers to key linkages among requirements between all stakeholders. It is well desi easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi ned in the Baldrige Categories to ensure consistency of plans, processes, measures, and actions. Integration builds on alignment so that the individual components of your performance management system operate in nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically a fully inter-dependently. Case Study on Systems Perspective This is the most challenging of all the eleven values and concepts. While most companies can operate its operation by units systematically, it still and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ struggles to align all the business unit to a fully integrated manner. It has been a regular exercise try to pull all business unit together as a whole, maintaining it is requires persistency and perseverance of a leade ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi rs. The Baldrige criteria form a unit model to assist in this integration effort. Its seven categories call for alignment between each other as well as across each others. However, companies lack understanding the these ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a build In integration of criteria categories hence neglected a focus effort to strive for improvement in the adoption of the categories to suit its business. Opportunity for Improvement Taking the Baldrige cri dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod teria as a fully integrated system, regular assessment of each categories would provide an feedback to companies where it needs improvement and the level of achievement would indicate a priority ranking. It is not attem cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin pted to score high in each categories but to strengthen the process and criteria requirement of each categories such that it build into the business systems. By doing so, it can sustain its effort to maintain a high stan tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen ard of fulfillment of the criteria requirements. In summary, a focus effort should be established by the leaders to constantly improvement the practices in the criteria requirements. Having understood all the Values and t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel Concepts of Malcolm Baldrige, it should be taken as a strategic issue to improve the adoption of the criteria and assess its deployment regularly. This concludes my write up of all the Eleven Values and concepts of Bal ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust drige Criteria. ---------------------------------------------------------------- Disclaimer: This article is written by the author based on his practical application experience. All definitions and interpretati y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products on of terminology are his point of view and has it has no intention to conflict with experts in similar topic. The author holds no responsibility for the use of this article in any way. Full Baldrige Criteria are availab . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de le at http://www.nist.gov/quality ----------------------------------------------------------------- Free to reprint or re-publish: All rights reserved. You are free to reprint or re-publish this article as long elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip as you include my resource box at the end of this article. And ensure that the URL in the resource box remained intact and it is linked to the author's website. --------------------------------------------------------- tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:The Best Advertising Money Can Buy is Absolutely Free! Background Checks: How They Can Determine Whether You Get Hired or Not! Anatomy of a Product: From an Idea to Reality
|